FOXO TECHNOLOGIES INC. Revenue from Contract with Customer, Excluding Assessed Tax
FOXO TECHNOLOGIES INC. (FOXO) reported Revenue from Contract with Customer, Excluding Assessed Tax of $4.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-14
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.72M, a 9.65% decline year-over-year.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $5.17M, a 63.03% increase year-over-year.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $4.43M, a 57.10% increase year-over-year.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.55M, a 196.55% increase year-over-year.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $16.37M, a 303.98% increase from fiscal 2024.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.05M, a 2688.61% increase from fiscal 2023.
- FOXO TECHNOLOGIES INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $145.29K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.72M 10-Q · filed 2026-08-14 | $9.88M 10-Q · filed 2026-08-14 | $14.31M derived: sum of 3 quarters · filed 2026-08-14 | $17.86M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $5.17M 10-Q · filed 2026-05-15 | $9.60M derived: sum of 2 quarters · filed 2026-05-15 | $13.15M derived: sum of 3 quarters · filed 2026-05-15 | $18.37M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $7.98M derived: sum of 2 quarters · filed 2026-04-15 | $13.20M derived: sum of 3 quarters · filed 2026-08-14 | $16.37M 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $3.55M 10-Q · filed 2025-11-10 | $8.77M derived: sum of 2 quarters · filed 2026-08-14 | $11.94M 10-Q · filed 2025-11-10 | $14.76M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $5.22M 10-Q · filed 2026-08-14 | $8.39M 10-Q · filed 2026-08-14 | $11.21M derived: sum of 3 quarters · filed 2026-08-14 | $12.41M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $3.17M 10-Q · filed 2026-05-15 | $5.99M derived: sum of 2 quarters · filed 2026-05-15 | $7.19M derived: sum of 3 quarters · filed 2026-05-15 | $7.21M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $4.02M derived: sum of 2 quarters · filed 2026-04-15 | $4.04M derived: sum of 3 quarters · filed 2026-04-15 | $4.05M 10-K · filed 2026-04-15 | |||
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-10 | $1.20M 10-Q · filed 2024-11-19 | $1.22M derived: sum of 2 quarters · filed 2025-11-10 | $1.23M 10-Q · filed 2025-11-10 | $1.23M 10-Q · filed 2024-11-19 | $1.34M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $27.47K 10-Q · filed 2025-08-19 | $28.00K 10-Q · filed 2024-08-19 | $34.65K 10-Q · filed 2025-08-19 | $35.00K 10-Q · filed 2024-08-19 | $144.94K derived: sum of 3 quarters · filed 2025-08-19 | $154.94K derived: sum of 4 quarters · filed 2025-08-19 | |
| 2024-03-31 | $7.18K 10-Q/A · filed 2025-08-19 | $117.47K derived: sum of 2 quarters · filed 2025-08-19 | $127.47K derived: sum of 3 quarters · filed 2025-08-19 | $139.47K derived: sum of 4 quarters · filed 2025-08-19 | |||
| 2023-12-31 | $110.29K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $120.29K derived: sum of 2 quarters · filed 2025-04-15 | $132.29K derived: sum of 3 quarters · filed 2025-04-15 | $145.29K 10-K · filed 2025-04-15 | |||
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-19 | $22.00K derived: sum of 2 quarters · filed 2024-11-19 | $35.00K 10-Q · filed 2024-11-19 | ||||
| 2023-06-30 | $12.00K 10-Q · filed 2024-08-19 | $25.00K 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |